ulcerative colitis, inflammatory bowel disease, IBD, UC Researchers performed a systematic review of clinical trials to assess the need for a consensus on the definition of mild to moderate, active ...
The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, published in Gastroenterology. This ...
Please provide your email address to receive an email when new articles are posted on . Zeposia (Ozanimod, Bristol Myers Squibb), the first sphingosine 1-phosphate (S1P) receptor modulator approved ...
AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
Zeposia is the first oral sphingosine-1-phosphate (S1P) receptor modulator to demonstrate benefit in moderate to severe ulcerative colitis in a Phase 3 study PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol ...
Please provide your email address to receive an email when new articles are posted on . Entyvio conferred superior clinical remission and mucosal healing compared with Humira among patients with ...
Everyday Health on MSN
Is stacking biologics safe if you have ulcerative colitis?
It’s becoming more common to treat ulcerative colitis with two biologic medications, or a biologic and a small molecule drug.
Etrasimod, an investigational selective sphingosine 1-phosphate (S1P) receptor modulator, led to clinically meaningful improvements in patients with moderately to severely active ulcerative colitis ...
Janssen announced new data from the phase 3 UNIFI maintenance study (N=523) which evaluated ustekinumab subcutaneous (SC) maintenance therapy in adults with moderate to severe ulcerative colitis (UC).
MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results